Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer

(MedPage Today) -- PARIS -- Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news